Gallium-68 prostate-specific membrane antigen ([⁶⁸Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study.

ABSTRACT:

Background

Prostate-specific membrane antigen (PSMA) is expressed in the microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic agent in patients with aggressive forms of thyroid cancer. The purpose of the current study was to determine the feasibility and utility of [⁶⁸Ga]Ga-PSMA-11 PET/MRI in thyroid cancer patients.

Methods

Eligible patients for this prospective pilot study were adults with a history of pathology-proven thyroid cancer who had abnormal radiotracer uptake on an 2-[¹⁸F]FDG PET and/or ¹³¹I scintigraphy performed in the 12 months prior to study enrollment. Patients underwent a [⁶⁸Ga]Ga-PSMA-11 PET/MRI, and comparison was made to the prior qualifying 2-[¹⁸F]FDG PET CT/MR

SUBMITTER: Lawhn-Heath C 

PROVIDER: S-EPMC7581659 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature